Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
72.1M
-
Number of holders
-
2
-
Total 13F shares, excl. options
-
7.56M
-
Shares change
-
-14.8K
-
Total reported value, excl. options
-
$24.3M
-
Value change
-
-$57.6K
-
Number of buys
-
1
-
Number of sells
-
-1
-
Price
-
$3.22
Significant Holders of Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share (OVID) as of Q4 2023
3 filings reported holding OVID - Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share as of Q4 2023.
Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share (OVID) has 2 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7.56M shares
of 72.1M outstanding shares and own 10.49% of the company stock.
Largest 10 shareholders include TAKEDA PHARMACEUTICAL CO LTD (7.53M shares), BVF INC/IL (6.85M shares), EcoR1 Capital, LLC (6.12M shares), Rubric Capital Management LP (5.32M shares), BlackRock Inc. (4.32M shares), Madison Avenue Partners, LP (3.65M shares), VANGUARD GROUP INC (2.99M shares), Artal Group S.A. (2.5M shares), ACADIAN ASSET MANAGEMENT LLC (1.66M shares), and JPMORGAN CHASE & CO (1.63M shares).
This table shows the top 2 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.